• Home
  • News
  • ASCIA anaphylaxis e-training for first aid (community)

ASCIA anaphylaxis e-training for first aid (community)

The Australasian Society of Clinical Immunology and Allergy (ASCIA) has developed ASCIA anaphylaxis training for first aid (community) in response to the recognised need for quality anaphylaxis training for the general community. This course provides ready access to high quality, consistent, reliable and evidence based anaphylaxis education throughout Australia and New Zealand.

It is available free of charge see the ASCIA website: www.allergy.org.au/patients/anaphylaxis-e-training-first-aid-community  

Anaphylaxis is a potentially life-threatening allergic reaction that requires urgent medical treatment. It is therefore essential to know how to recognise and respond to an anaphylaxis emergency as well as implement appropriate risk minimisation strategies to prevent exposure to known allergens.

ASCIA anaphylaxis e-training for first aid (community) has been designed to be undertaken by the broader community such as parents, friends, carers, patients, workplace or student colleagues, and club members.

The ASCIA President, Clinical Associate Professor Richard Loh stated "It is important to increase awareness of anaphylaxis in the broader community. This course has therefore been developed to help patients, parents, carers and other community members manage life-threatening allergic reactions by educating people about how to identify and respond to anaphylaxis."

Development of ASCIA anaphylaxis e-training for first aid (community) has included an extensive review process with ASCIA members and patient support organisations throughout Australasia.

Information about anaphylaxis is available on the ASCIA website Anaphylaxis Resources section www.allergy.org.au/health-professionals/anaphylaxis-resources which includes parent/patient fact sheets, the latest versions of ASCIA Action Plans for Anaphylaxis, ASCIA Action Plans for Allergic Reactions, FAQ and instructions on how to use adrenaline autoinjectors.

©2023 Allergy and Immunology Foundation of Australasia